Chapter 6
Epidemiology, Etiology, and Natural History of Cholangiocarcinoma
Peter Neuhaus MD,
Ulf P. Neumann MD,
Daniel Seehofer MD,
Peter Neuhaus MD
Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Campus Virchow - Klinikum, Berlin, Germany
Search for more papers by this authorUlf P. Neumann MD
Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Campus Virchow - Klinikum, Berlin, Germany
Search for more papers by this authorDaniel Seehofer MD
Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Campus Virchow - Klinikum, Berlin, Germany
Search for more papers by this authorPeter Neuhaus MD,
Ulf P. Neumann MD,
Daniel Seehofer MD,
Peter Neuhaus MD
Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Campus Virchow - Klinikum, Berlin, Germany
Search for more papers by this authorUlf P. Neumann MD
Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Campus Virchow - Klinikum, Berlin, Germany
Search for more papers by this authorDaniel Seehofer MD
Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Campus Virchow - Klinikum, Berlin, Germany
Search for more papers by this authorBook Editor(s):Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Stefan Breitenstein MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorFirst published: 09 December 2009
Summary
This chapter contains sections titled:
-
Epidemiology
-
Etiology
-
Natural history
-
Self-assessment questions
-
References
-
Self-assessment answers
References
- Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.
- Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353–7.
- Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 2001; 48: 816–20.
- Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472–7.
- Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115–25.
- de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341: 1368–78.
- Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
- Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806–13.
- Strom BL, Hibberd PL, Soper KA, Stolley PD, Nelson WL. International variations in epidemiology of cancers of the extrahepatic biliary tract. Cancer Res 1985; 45: 5165–8.
- Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303–14.
- Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997; 32: 1042–5.
- Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610–15.
- Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27: 311–16.
- Soreide K, Korner H, Havnen J, Soreide JA. Bile duct cysts in adults. Br J Surg 2004; 91: 1538–48.
- Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10 (Suppl 4): S308–S 311.
- Watanapa P, Watanapa WB. Liver fl uke-associated cholangiocarcinoma. Br J Surg 2002; 89: 962–70.
- Parkin DM, Srivatanakul P, Khlat M, et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991; 48: 323–8.
- Thamavit W, Bhamarapravati N, Sahaophong S, Vajrasthia S, Angsuhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini infected Syrian golden hamsters. Cancer Res 1978; 38: 4634–9.
- Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a casecontrol study in Pusan, Korea. Int J Epidemiol 1996; 25: 933–40.
- Tabata M, Nakayama F. Bacteria and gallstones. Etiological signifi cance. Dig Dis Sci 1981; 26: 218–24.
-
Sugihara S, Kojiro M. Pathology of cholangiocarcinoma. In: Okuda K, Ishak KG, eds. Neoplasms of the Liver. Tokyo: Springer Verlag, 1987.
10.1007/978-4-431-68349-0_11 Google Scholar
- Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria – an epidemiological investigation. Br J Cancer 1984; 50: 389–97.
- Uchida T, Shikata T, Tanaka E, Kiyosawa K. Immunoperoxidase staining of hepatitic C virus in formalin-fi xed, paraffinembedded needle liver biopses. Virchow Arch 1994; 424: 465–9.
-
Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000; 88: 2471–7.
10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12: 959–64.
- Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28: 921–5.
- Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620–6.
- Lee SS, Kim MH, Lee SK, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer 2004; 100: 783–93.
-
Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214–18.
10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin defi ciency. Am J Surg Pathol 1998; 22: 742–8.
- Bond GG, McLaren EA, Sabel FL, et al. Liver and biliary tract cancer among chemical workers. Am J Ind Med 1990; 18: 19–24.
- Jinawath N, Chamgramol Y, Furukawa Y, et al. Comparison of gene expression profi les between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 2006; 44: 1025–38.
- Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781–2.
- Isa T, Tomita S, Nakachi A, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002; 49: 604–8.
- Sandhu DS, Shire AM, Roberts LR. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identifi cation of treatment targets. Liver Int 2008; 28: 12–27.
- Shaib YH, Davila JA, Henderson L, McGlynn KA, El-Serag HB. Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the United States: a population-based study. J Clin Gastroenterol 2007; 41: 911–17.
- Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355–63.
